Studies expand the therapeutic potential of apramycin

Together with partners from the ENABLE project consortium, researchers at the Latvian Institute of Organic Synthesis for the first time present results that prove the efficacy of drug candidate EBL-1003 (apramycin) in urinary tract infections. Apramycin is an aminoglycoside antibiotic that demonstrated preclinical efficacy in lung infection models and in 2020 it completed Phase I clinical trials with positive results.

In the latest study, scientists have compared the efficacy of apramycin with the known medicine gentamicin which is used for the treatment of complicated urinary tract infections. They discovered that apramycin and gentamicin showed similar results against the uropathogen E. coli J96, whereas apramycin nephrotoxicity in adult rats was significantly lower than that of gentamicin. This suggests a wider therapeutic window for EBL-1003 than for gentamicin in the treatment of urinary tract infections. The research is published in the journal “EBioMedicine” (IF=8.14).

Apramycin is developed by Swiss start-up Juvabis in collaboration with the ENABLE consortium, a public-private partnership funded by the Innovative Medicines Initiative (IMI), focused on accelerating the development of new antibiotics for the treatment of Gram-negative systemic infections.

Read the article:

Becker, K.; Cao S., Nilsson, A.; Erlandsson, M.; Hotop, S.-K.; Kuka, J.; Hansen, J.; Haldimann, K.; Grinberga, S.; Berruga-Fernández, T.; Huseby, D.L.; Shariatgorji, R.; Lindmark, E.; Platzack, B.; Böttger, E.C.; Crich, D.; Friberg, L.E.; Vingsbo Lundberg, C.; Hughes, D.; Brönstrup, M.; Andrénc, P.E.; Liepinsh, E.; Hobbie, S.N.
Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis.
EBioMedicine 2021, 73, 103652. DOI: 10.1016/j.ebiom.2021.103652